[Congressional Record Volume 167, Number 145 (Tuesday, August 10, 2021)]
[Senate]
[Page S6389]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 3635. Mr. BENNET (for himself, Ms. Hassan, Mr. Warnock, Mr. Kelly, 
and Ms. Cortez Masto) submitted an amendment intended to be proposed by 
him to the concurrent resolution S. Con. Res. 14, setting forth the 
congressional budget for the United States Government for fiscal year 
2022 and setting forth the appropriate budgetary levels for fiscal 
years 2023 through 2031; which was ordered to lie on the table; as 
follows:

       At the end of title III, add the following:

     SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO LOWERING 
                   PRESCRIPTION DRUG PRICES UNDER MEDICARE.

       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution, 
     and make adjustments to the pay-as-you-go ledger, for one or 
     more bills, joint resolutions, amendments, amendments between 
     the Houses, motions, or conference reports relating to 
     lowering drug prices, increasing equitable access to 
     affordable and innovative pharmaceuticals, and reducing 
     patient cost-sharing and government spending through 
     providing the Secretary of Health and Human Services with the 
     authority to negotiate drug prices under title XI of the 
     Social Security Act, provided that such legislation would not 
     increase the deficit over either the period of the total of 
     fiscal years 2022 through 2026 or the period of the total of 
     fiscal years 2022 through 2031.
                                 ______